Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
March 18, 2025 | 05:52
Telix Pharmaceuticals Limited today announces that the Brazilian Health Regulatory Agency has approved Illuccix® the Company's lead prostate cancer imaging agent.
Mobile Version
